Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
79834.510.0076%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

Enliven Therapeutics Inc

ELVNNASDAQ
Trade with Public
Trade with Public
$59.32
-0.33-0.55%
At close: Sep 4, 5:00 PM EST
$59.32
N/A
After Hours: Sep 4, 4:00 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Enliven Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Enliven Therapeutics (ELVN).

Price Target Range — 9 Quarters

Analyst Consensus — 10 Analysts

10Buy
Consensus RatingBuy# Analysts10Avg. Consensus PT$65Upside to Avg. PT+8.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 18, 2026William BlairAndy HsiehInitiateOutperform—
Aug 18, 2026BarclaysEtzer DaroutInitiateOverweight$78
More with Benzinga EdgeGet Access

Analyst Ratings News

Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says

William Blair initiates Enliven Therapeutics (ELVN) with Outperform, highlighting ELVN-001's strong CML trial data & $8.8B market potential.
Vandana Singh

PRO
William Blair Initiates Coverage On Enliven Therapeutics with Outperform Rating

William Blair analyst Andy Hsieh initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Outperform rating.
Benzinga Newsdesk

PRO
Barclays Initiates Coverage On Enliven Therapeutics with Overweight Rating, Announces Price Target of $78

Barclays analyst Etzer Darout initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Overweight rating and announces Price Target of $78.
Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Enliven Therapeutics, Raises Price Target to $73

Mizuho analyst Salim Syed maintains Enliven Therapeutics (NASDAQ:ELVN) with a Outperform and raises the price target from $62 to $73.
Benzinga Newsdesk

PRO
Stifel Maintains Buy on Enliven Therapeutics, Raises Price Target to $82

Stifel analyst Dara Azar maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price target from $80 to $82.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Enliven Therapeutics, Lowers Price Target to $78

Guggenheim analyst Michael Schmitz maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and lowers the price target from $80 to $78.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved